Prime Medicine Gets FDA Clearance to Start Human Testing of PM647 for Alpha-1 Antitrypsin Deficiency
First human data are due in 2027. This is not an approval; Beam remains ahead in patients.
/ 6 items
#PRME↓
Gene-Editing Stocks Fall After Anthropic Says Claude Found a CRISPR-Like Enzyme System
Early lab results show Claude found a CRISPR-like repeat array tied to a reverse transcriptase. No proven editing tool yet.
BMO Capital Bullish on Prime Medicine: Outperform Rating, $9 Target, and 2027 Clinical Catalysts
BMO cited Prime Medicine's unique prime-editing technology, which enables precise DNA corrections without creating double-strand breaks.
Prime Medicine Wins Arbitration Dispute with Beam Therapeutics, Clears Path for PM647
Prime Medicine secures positive arbitration ruling against Beam Therapeutics: no damages owed for PM647 in AATD. IND/CTA filing planned for Q3 2026, first clinical data in 2027.
Prime Medicine Gets Analyst Upgrade to Buy as First In Vivo Prime Editing Trial Moves Forward
H.C. Wainwright cites New Zealand clearance for PM577a — the first in vivo Prime Editing clinical trial for Wilson’s disease.
FDA’s New Fast-Track Plan for Custom Gene Editing Could Transform Rare Disease Treatments
The FDA is unveiling a faster approval pathway for custom gene-editing therapies, aiming to spark major investment and accelerate cures for rare diseases through Crispr-based innovations.